In a trio of guidances released Monday, the FDA laid out new recommendations for research on cancer drugs, including how to develop drugs for acute myeloid leukemia (AML), how to classify the side effects of immunotherapies and best practices for developing therapies targeting biomarkers across multiple cancer types.
Source: Drug Industry Daily